{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T23:26:51Z","timestamp":1715988411507},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7176,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1023\/a:1008355413788","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"535-540","source":"Crossref","is-referenced-by-count":16,"title":["A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck"],"prefix":"10.1016","volume":"11","author":[{"given":"A.D.","family":"Colevas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Adak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.C.","family":"Amrein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Barton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.R.","family":"Posner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008355413788_bb0005","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3322\/canjclin.48.1.6","article-title":"Cancer statistics, 1998","volume":"48","author":"Landis","year":"1998","journal-title":"CA Cancer J Clinicians"},{"key":"10.1023\/A:1008355413788_bb0010","series-title":"Principles and Practices of Oncology","first-page":"574","article-title":"Cancer of the head and neck","author":"Schantz","year":"1993"},{"key":"10.1023\/A:1008355413788_bb0015","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0889-8588(18)30408-8","article-title":"Chemotherapy for recurrent and metastatic head and neck cancer","volume":"5","author":"Pinto","year":"1991","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1023\/A:1008355413788_bb0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bjc.1990.59","article-title":"A phase III randomized trial of cisplatin, methotrexate, cisplatin + methotrexate and cisplatin + 5-FU in end stage squamous carcinoma of the head and neck","volume":"61","year":"1990","journal-title":"B J Cancer"},{"key":"10.1023\/A:1008355413788_bb0025","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","article-title":"Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A southwest oncology group study","volume":"10","author":"Forastiere","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008355413788_bb0030","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/1097-0142(19810901)48:5<1061::AID-CNCR2820480502>3.0.CO;2-X","article-title":"A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer","volume":"48","author":"DeConti","year":"1981","journal-title":"Cancer"},{"key":"10.1023\/A:1008355413788_bb0035","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1992.10.2.257","article-title":"A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous-cell carcinoma of the head and neck","volume":"10","author":"Jacobs","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008355413788_bb0040","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/1097-0142(19840501)53:9<1819::AID-CNCR2820530903>3.0.CO;2-R","article-title":"Cisplatin and 5-fluorouracil infusion in patients with recurrent and desseminated epidermoid cancer of the head and neck","volume":"53","author":"Kish","year":"1984","journal-title":"Cancer"},{"key":"10.1023\/A:1008355413788_bb0045","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00000421-198810000-00009","article-title":"Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer","volume":"11","author":"Kish","year":"1988","journal-title":"Am J Clin Oncol"},{"key":"10.1023\/A:1008355413788_bb0050","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/1097-0142(19851215)56:12<2740::AID-CNCR2820561203>3.0.CO;2-Y","article-title":"A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous-cell carcinoma of the head and neck","volume":"56","author":"Kish","year":"1985","journal-title":"Cancer"},{"key":"10.1023\/A:1008355413788_bb0055","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/oxfordjournals.annonc.a058908","article-title":"Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous-cell carcinoma of the head and neck","volume":"5","author":"Catimel","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008355413788_bb0060","first-page":"315","article-title":"A phase II study of Docetaxel in squamous-cell carcinoma (SCC) of the head and neck","volume":"15","author":"Couteau","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008355413788_bb0065","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1200\/JCO.1996.14.5.1672","article-title":"Docetaxel: An active drug for squamous-cell carcinoma of the head and neck","volume":"14","author":"Dreyfuss","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008355413788_bb0070","first-page":"298","article-title":"An early phase II study of docetaxel (Taxotere) in patients with head and neck cancer","volume":"14","author":"Fujii","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008355413788_bb0075","first-page":"41","article-title":"A phase II trial of paclitaxel in squamous-cell carcinoma of the head and neck with correlative laboratory studies","volume":"22","author":"Smith","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008355413788_bb0080","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2270::AID-CNCR24>3.0.CO;2-Q","article-title":"Final report of a phase II evaluation of paclitaxel in patients with advanced squamous-cell carcinoma of the head and neck","volume":"82","author":"Forastiere","year":"1998","journal-title":"Cancer"},{"key":"10.1023\/A:1008355413788_bb0085","first-page":"327","article-title":"Docetaxel (RP 56976, Taxotere) efficacy as a single agent or in combination against mammary tumors in mice","volume":"35","author":"Bissery","year":"1994","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1023\/A:1008355413788_bb0090","first-page":"3","article-title":"Preclinical profile of Docetaxel (Taxotere): Efficacy as a single agent and in combination","volume":"22","author":"Bissery","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008355413788_bb0095","first-page":"490","article-title":"A phase I study of docetaxel (Taxotere) and 5-FU combination chemotherapy in patients with advanced solid tumors","volume":"15","author":"Peacock","year":"1996","journal-title":"Proc ASCO"},{"key":"10.1023\/A:1008355413788_bb0100","first-page":"1127","article-title":"Bergman M, Huhtala S","volume":"17","author":"Salminen","year":"1999","journal-title":"Ekholm E. Docetaxel: Standard recommendation dose of 100 mg\/m2 is effective but not feasible for some metastatic breast cancer patients heavily pre-treated with chemotherapy \u2013 a phase II single-center study. J Clin Oncol"},{"key":"10.1023\/A:1008355413788_bb0105","first-page":"422","article-title":"Higgins BP et al","volume":"14","author":"Trudeau","year":"1996","journal-title":"Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol"},{"key":"10.1023\/A:1008355413788_bb0110","first-page":"650","article-title":"A multicentre phase II study of docetaxel 75 mg\/m2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC","volume":"74","author":"Dieras","year":"1996","journal-title":"European Organization for Research and Treatment of Cancer. Br J Cancer"},{"key":"10.1023\/A:1008355413788_bb0115","first-page":"795","article-title":"Ifosfamide in advanced head and neck cancer","volume":"24","author":"Verweij","year":"1998","journal-title":"A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group. Eur J Cancer Clin Oncol"},{"key":"10.1023\/A:1008355413788_bb0120","first-page":"24","article-title":"Single-agent paclitaxel and paxlitaxel plus ifosfamide in the treatment of head and neck cancer","volume":"22","author":"Forastiere","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008355413788_bb0125","first-page":"15","article-title":"Athanasiadis I","volume":"7","author":"Vokes","year":"1996","journal-title":"Chemotherapy for squamous-cell carcinoma of head and neck: The future is now. Ann Oncol"},{"key":"10.1023\/A:1008355413788_bb0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1008360323986","article-title":"Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent, or metastatic squamous-cell carcinoma of the head and neck","volume":"10","author":"Schoffski","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008355413788_bb0135","first-page":"521","article-title":"Randomized comparison of cisplati","volume":"5","author":"Clavel","year":"1994"},{"key":"10.1023\/A:1008355413788_bb0140","first-page":"955","article-title":"Hong W","volume":"6","author":"Paredes","year":"1988","journal-title":"Felder T et al. Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocabramate in recurrent and\/or metastatic squamous-cell cancer of the head and neck. J Clin Oncol"},{"key":"10.1023\/A:1008355413788_bb0145","first-page":"1054","article-title":"Johnson J","volume":"16","author":"Schrijvers","year":"1998","journal-title":"Jimenez U et al. Phase III trial of modulation of cisplatin-fluorouracil chemotherapy by inter-feron-\u03b1\u20132b in patients with recurrent or metastatic head and neck cancer. J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419550566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419550566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/11\/5\/535\/19478194\/11-5-535.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:15:42Z","timestamp":1582182942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419550566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["S0923753419550566"],"URL":"https:\/\/doi.org\/10.1023\/a:1008355413788","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}